In the present study, we report that media conditioned by polycythemia vera (PV) CD3 þ cells promote BFU-E and CFU-Mk colony formation by both cord blood and PV peripheral blood CD34 þ cells in the absence of exogenous cytokines and promoting megakaryocyte proplatelet formation. CD3 þ cells constitutively produce elevated levels of IL-11, while stimulation with the addition of phytohemagglutinin (PHA) increased GM-CSF levels in most of the patients with PV. Anti-IL-11-neutralizing antibody partially inhibited the formation of BFU-E and CFU-Mk colonies promoted by PV CD3 þ cell-conditioned media. Although IL-11 is not produced by normal T cells, realtime PCR and flow cytometric analysis showed that IL-11 was upregulated in the CD3 þ cells of most PV patients as compared to normal CD3 þ cells. In addition, a greater percentage of BFU-E colonies formed by PV CD34 þ cells in the presence of PV CD3 þ cell-conditioned media alone were JAK2V617F-positive as compared with that induced by EPO. We conclude that dysregulated production of soluble growth factor(s), including IL-11 and GM-CSF by PV T cells, contributes to the in vitro formation of erythroid colonies in the absence of exogenous cytokines by PV CD34 þ cells and likely plays a role in sustaining hematopoiesis in PV.
Introduction
Polycythemia vera (PV) is a Philadelphia chromosome negative (Ph À ) myeloproliferative disorder (MPD) resulting from the transformation of a multipotent hematopoietic stem cell (HSC). This clonal disorder is characterized by trilineage bone marrow (BM) hyperplasia associated with increased production of red cells, granulocytes and platelets. [1] [2] [3] [4] [5] Recently, a somaticactivating mutation of the JAK2 tyrosine kinase, resulting from a valine to phenylalanine substitution within the regulatory pseudo kinase domain (JAK2V617F), has been identified in more than 90% of the patients with PV and 30-50% of the patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IM). [6] [7] [8] [9] [10] The currently available data clearly indicate that the JAK2V617F mutation plays a pivotal role in the pathogenesis of the Ph À MPDs. 7, 11, 12 The JAK2 mutation itself, however, does not likely entirely account for the development of PV. [13] [14] [15] [16] Clonality studies have demonstrated that the Ph À MPDs are biologically interrelated clonal HSC disorders, which involve each of the myeloid cell types (granulocytes, erythrocytes, platelets and monocytes) [17] [18] [19] [20] [21] and that B 22 and T lymphocytes [23] [24] [25] can also occasionally be involved in the malignant process in patients with Ph À MPDs. Using 9p, 10q and 11q loss of heterozygosity (LOH) as clonality markers, Kralovics et al. 26 have also shown that a minor proportion of T cells are derived from the PV clone in some patients with PV. Recently, we have also demonstrated that the JAK2V617F mutation is present in the cells belonging to the various myeloid lineages in the majority of patients with PV, but that this mutation is also present in B and T lymphocytes in a subpopulation of patients with PV. 13 One of the defining characteristics of PV is the ability of BM and peripheral blood (PB) mononuclear cells (MNC) to form erythroid colonies in vitro in the absence of the addition of exogenous cytokines. 1, 4, 5 These so-called endogenous erythroid colonies (EEC) have been shown to be partially dependent on the presence of accessory cells within the BM and PB MNC. [27] [28] [29] [30] Ugo et al. 31 reported that unlike BM MNCs, PV CD34 þ cells were incapable of forming EEC in the absence of growth factors. These findings are surprising in the face of the JAK2V617F-activating mutation, which is presumably responsible for the enhanced erythropoiesis in PV. Several groups have reported that soluble factors secreted by BM accessory cells might contribute to the formation of EEC. [27] [28] [29] [30] EEC formation by PV MNC has been shown to be decreased by removal of adherent cells and restored by readdition of adherent cells or adherent cell-conditioned media. 27, 28 Hermouet et al. 29 have first reported that serum interleukin-11 (IL-11) and IL-8 levels were elevated in PV patients and that BM stromal cells of PV patients produced significantly larger amounts of IL-11 and IL-8 than that of normal donors. Cassel et al. 32 also demonstrated that soluble factors were elaborated from PB PV T cells that stimulate burstforming unit erythroid (BFU-E) formation by normal BM cells. Normal T cells are also known to produce a variety of cytokines that influence various stages of blood cell development. 32 We therefore attempted to examine further the possible role of PV T cells in the formation of EEC by PB CD34 þ cells. In the present study, we report that media conditioned by PV CD3 þ cells promote BFU-E and colony-forming unit megakaryocyte (CFU-Mk) formation by both cord blood (CB) and PV PB CD34 þ cells in the absence of exogenous cytokines as well as promote megakaryocyte proplatelet formation. We also found that a greater percentage of BFU-E colonies were JAK2V617F-positive when PV CD34 þ cells were assayed in the presence of PV CD3 þ cell-conditioned media alone as compared with those assayed in the presence of erythropoietin (EPO) alone. In most of the patients with PV, CD3 þ cell-conditioned media contained elevated levels of IL-11. Furthermore, the addition of anti-IL-11-neutralizing antibody partially inhibited the formation of BFU-E and CFU-Mk promoted by PV CD3 þ cell-conditioned media. IL-11 is a multifunctional cytokine produced by BM stromal cells, fibroblasts and osteoblasts, but not previously recognized to be produced by T cells. 29, 33 We conclude that dysregulated production of soluble growth factor(s) by PV T cells, not involving JAK2V617F, contributes to the in vitro formation of EEC by PV CD34 þ cells. This study provides evidence to support the hypothesis that the production of cytokines by PV T cells contributes to PV hematopoietic cell development.
Materials and methods

Patients and normal donors
All human tissue samples were obtained after informed consent was provided according to the guidelines of the Institutional Review Board of the University of Illinois College of Medicine. All patients met the WHO diagnostic criteria for PV and were treated solely with phlebotomy. 1, 3, 4 Phlebotomized units of blood (400-600 ml) were obtained from each of the PV patients during their routine care. PB samples were also obtained from healthy volunteers. MNCs isolated from normal volunteers mobilized with granulocyte colony-stimulating factor G-CSF were obtained from Amgen (Thousand Oaks, CA, USA). Human CB samples were obtained from the New York Blood Center (New York, NY, USA).
Purification of human CB and PB CD34
þ and CD3 ) were incubated in 1 ml Iscove's modified Dulbecco's media (IMDM) containing either 1 or 0.1% bovine serum albumin (BSA), with or without phytohemagglutinin (PHA, 2 mg/ml) in 24-well tissue plates (Corning, Acton, MA, USA) at 371C in 5% CO 2 . Media was collected after 72 h of incubation following centrifugation and stored in aliquots at À801C.
JAK2V617F mutational analysis
The presence of JAK2V617F mutation was determined in the PB granulocytes of patients with PV as described previously. 13 The PB CD3 þ cells isolated from the patients with PV were also analyzed for the presence of JAK2V617F mutation. Briefly, genomic DNA (gDNA) was extracted from granulocytes or CD3 þ cells using Easy-DNA Kit (Invitrogen, Carlsbad, CA, USA) and was amplified using PCR primers 5 0 -GATCTCCATATT CCAGGCTTACACA-3 0 and 5 0 -TATTGTTTGGGCATTGTAACC TTCT-3 0 , which cover exon 14 of the JAK2 gene and give rise to a PCR product of 520 bp. PCR was performed with DNA polymerase iTaq (Bio-Rad, Hercules, CA, USA). The PCR products were gel-purified and sequenced directly using the ABI 3730 Â l DNA analyzer at the DNA Sequencing Facility of the University of Illinois at Chicago. The granulocytes of all of the 12 PV patients, whose cells were used in this study, contained the JAK2V617F mutation, while the PV PB CD3 þ cells from each of the PV patient were negative for JAK2V617F except one, PV9, as we reported recently. 13 Hematopoietic progenitor cell assays in the presence of media conditioned by CD3 þ cells CD34 þ cells isolated from CB and PV PB were assayed for hematopoietic progenitor cells using Methocult (StemCell Technologies) according to the manufacturer's instructions. One milliliter of culture mixture containing CD34 þ cells and 20% CD3
þ cell-conditioned media were plated into 35-mm standard non-tissue culture dishes (Nunc, Roskilde, Denmark) in the absence of exogenous cytokines or in the presence of stem cell factor (SCF; 100 ng/ml), EPO (2 U/ml) or SCF plus thrombopoietin (TPO; 100 ng/ml), and incubated at 371C in a humidified atmosphere flushed with 5% CO 2 in air. All the cytokines utilized were a gift from Amgen. Media conditioned by normal PB CD3 þ cells and media (IMDM) alone served as controls. All cultures were performed in triplicate and the number of colonies enumerated after 12-14 days of culture according to criteria reported previously. 34 In separate experiments, hematopoietic progenitor cell assays were performed with CB CD34 þ cells and 20% PV CD3 þ cell-conditioned media in the presence or absence of anti-IL-11 (1 mg/ml), antigranulocyte monocyte CSF (GM-CSF; 1 mg/ml), and/or anti-IL-6 (1 mg/ml)-neutralizing antibodies individually or in combination (R&D, Abingdon, UK).
Genotype for the JAK2V617F-positive or -negative colonies by nested allele-specific PCR Individual BFU-E colonies formed by PB CD34 þ cells in the presence of PV CD3 þ cell-conditioned media or EPO were randomly plucked from the semisolid media and gDNA was isolated by using the Extract-N-Amp Blood PCR Kits (Sigma, St Louis, MO, USA). The JAK2V617F mutation was detected by using nested allele-specific PCR as we described previously. 35 Briefly, a 521 bp DNA fragment containing the V617F mutation site was amplified from the gDNA using primers P1, 5 0 -GATCTCCATATTC CAGGCTTACACA-3 0 ; and P1r, 5 0 -TATTGTTTGGGCATTGTA ACCTTCT-3 0 . After 35 cycles consisting of 30 s at 951C, 30 s at 601C and 30 s at 721C, 0.5 ml of PCR products were further amplified by nested and allele-specific primers of P2, 5 0 -CCT CAGAACGTTGATGGCA-3 0 ; P2r, 5 0 -ATTGCTTTCCTTTTTCACAA GA-3 0 ; Pnf, 5 0 -AGCATTTGGTTTTAAATTATGGAGTATATG-3 0 ; and Pmr, 5 0 -GTTTTACTTACTCTCGTCTCCACAAAA-3 0 , following 35 cycles of 951C for 30 s, 591C for 25 s, and 721C for 25 s. The final PCR products were analyzed on 2.5% agarose gels and contained 453, 279 and 229 bp products. A 279 bp product was indicative of the JAK2V617F-specific allele, while a 229 bp product denoted wild-type-specific allele. Colonies were classified as homozygous for JAK2V617F if they contained only the 279 bp band, while heterozygous colonies were identified based upon the presence of both the 279 and 229 bp bands.
Flow cytometric analysis
The activation status of the PB CD3 þ cells from patients with PV and normal volunteers were determined flow cytometrically using mAbs including CD3, CD45RO, CD25 and HLA-DR. PB MNC of PV patients or normal volunteers were suspended in PBS containing 0.1% BSA and incubated in 20% rabbit serum and 20% human serum for 30 min at 41C. The blocked cells were then incubated with a panel of mAbs against the following human cell markers conjugated to fluorescein-5-isothiocyanate (FITC) or phycoerythrin (PE) CD3, CD45RO, CD25, HLA-DR, CD4 and CD8 (Becton Dickinson, San Jose, CA, USA) for 30 min at 41C. A separate cell aliquot was also stained with isotypematched mAbs labeled with the same fluorochromes and after washing, 2 mg/ml propidium iodide (PI) was added after washing. The samples were then analyzed flow cytometrically using a FACSCalibur (Becton Dickinson, Mountain View, CA, USA). Routinely, 30 000 events were acquired per sample.
IL-11 intracellular staining was performed following the protocol recommended by the manufacturer (anti-IL-11 Kit and IntraPrep Permeabilization Reagent (Becton Dickinson). Normal and PV MNC were washed and blocked with PBS containing 7.5% BSA and 0.5 M ethylenediamine tetraacetic acid. The cells were then stained with CD3-FITC or an isotype control for 30 min at 41C. After washing, cells were fixed and permeabilized, followed by intracellular staining with anti-IL-11-PE or control immunoglobulin G (IgG)2-PE mAb (Becton Dickinson) for 45 min at room temperature. Cells were then washed and resuspended in PBS containing 0.5% formaldehyde and analyzed flow cytometrically.
ELISA assays
CD3
þ cell-conditioned media (0.1% BSA with or without PHA) were assayed by enzyme-linked immunosorbent assay (ELISA)_ in duplicate or triplicate using the Quantikine IL-3 kit and IL-6 kit, ELISA kits against SCF, soluble IL-6 receptor (sIL-6R), IL-8, IL-11, GM-CSF, insulin-like growth factor-1 (IGF-1), TPO (R&D), and EPO (StemCell Technologies Inc.) according to the manufacturer's instructions.
Quantitative real-time RT-PCR assay of IL-11 mRNA
Total RNA was extracted from normal or PV CD3 þ cells using a PicroPureTM RNA Isolation Kit (Arcturus Bioscience, Mountain View, CA, USA). First-strand complimentary DNA (cDNA) was synthesized from total RNA with SuperScriptTM b reverse transcriptase (Invitrogen) according to the manufacturer's instructions. The sequences of the primers used for the amplification were as follows: IL-11, (162 bp) 5
The quantitative real-time reverse transcription (RT)-PCR assays were performed with the ABI Prism 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), and the PCR products were detected by use of SYBR green technology (ABI, Foster City, CA, USA). Cycling conditions included initial denaturation at 951C for 10 min, then by 40 cycles of denaturation at 951C for 15 s, annealing at 561C for 30 s, and extension at 721C for 30 s. All assays were performed in triplicate and a negative control was included in each assay. To quantitate IL-11 mRNA expression in relation to an internal control, an amplification standard curve of the reference gene b-actin was established as described previously. 36, 37 The IL-11 mRNA expression was quantitated by measuring the threshold cycle and presented as relative rates compared with the expression of the reference gene b-actin.
Statistical analysis
The results were expressed as the mean7s.d. of data obtained from varying numbers of individual experiments. Differences between percentages were calculated using the Wilcoxon test, whereas differences between other groups were compared using either a Student's t-test or analysis of variance (ANOVA). Statistical significance was achieved for Po0.05.
Results
PV CD3
þ T cells-conditioned media promotes BFU-E-, CFU-Mk-and CFU-Mix-derived colony formation
We attempted to explore if PV T cells elaborate growth factors that stimulate hematopoietic colony formation by CD34 þ cells. Serum-free-conditioned media were prepared with CD3 þ T cells isolated from the PB of patients with PV and normal donors. CB CD34 þ cells or PV PB CD34 þ cells were assayed in semisolid media in the absence of exogenous cytokines but in the presence of media conditioned by PV T cells, normal T cells or media alone.
As can be seen in Table 1 Figure 1a) , which was not observed in the megakaryocyte-containing colonies, which developed in the presence of SCF and TPO (Figure 1b) . Figure 1c is a photomicrograph of a typical BFU-E colony assayed from CB CD34 þ cells in the presence of PV CD3 þ cell-conditioned medium and in the absence of exogenous cytokines.
PV CD3 þ cell-conditioned media had a similar effect on in vitro hematopoietic colony formation by PV PB CD34 þ cells. As can be seen in Table 2, PV CD34 þ cells did not form EEC in the presence of media alone. The addition of normal CD3 þ cellconditioned media or SCF alone leads to the appearance of a limited numbers of BFU-E, but no megakaryocyte-containing colonies. By contrast, PV CD3 þ cell-conditioned media lead to a fourfold greater number of EEC as compared to normal CD3 þ cell-conditioned media and the appearance of megakaryocytecontaining colonies. + cells (n ¼ 3) were cultured in methylcellulose culture media in the presence of media conditioned by normal or PV CD3 + cells in the absence of exogenous cytokines. Colonies were enumerated after 12-14 days of culture. Each data point represents the mean7s.d. of three independent experiments. *Significant differences between cultures containing normal-conditioned media and PV-conditioned media (Po0.05).
To determine the effect of PV CD3 þ cell-conditioned media on JAK2V617F-positive PV progenitor cells, gDNAs were extracted from BFU-E colonies randomly plucked from cultures of PV CD34 þ cells assayed in the presence of PV CD3 þ cellconditioned media alone or EPO alone. The JAK2V617F mutational status of individual colonies was analyzed using a highly sensitive nested allele-specific PCR. As shown in Figure 2 , a greater percentage of BFU-E colonies formed by PV CD34 þ cells in the presence of PV CD3 þ cell-conditioned media were JAK2V617F-positive as compared with the colonies cloned in the presence of EPO.
These data indicate that a soluble factor(s) produced by PV T cells preferentially support erythropoiesis and megakaryocytopoiesis, which might contribute to the excessive production of erythroid and megakaryocytic cells by hematopoietic cells belonging to the malignant PV clone.
The BFU-E-and CFU-Mk-promoting activity present in the PV CD3 þ cell-conditioned media is not likely due to the altered activation status of PV CD3 þ cells Activated normal T cells are known to elaborate growth factors promoting hematopoietic colony formation. 38 To examine if the BFU-E-and CFU-Mk-promoting activity present in the media conditioned by PV CD3 þ cells was due to the altered T-cell activation in PV, a phenotypic analysis of primary CD3 Table 3 ). In addition, the percentage of CD3 þ cells expressing CD25, CD45RO or HLA-DR were similar for both PV and normal samples before and after incubation ( Supplementary Figure 1; P40.05), indicating there is no change in CD3 þ cell activation status after 72 h of incubation. The percentages of PV CD3 þ cells, which were activated in PV, therefore, appear to be similar to those of normal control CD3 þ cells, suggesting that the BFU-Eand CFU-Mk-promoting activity present in the PV CD3 þ cellconditioned media is not merely a consequence of the altered activation status of PV CD3 þ cells.
CD3 þ T cells produce higher levels of IL-11 and GM-CSF in most of the patients with PV
To identify the factor(s) responsible for the formation of BFU-E and megakaryocyte-containing colonies by PV CD3 þ cellconditioned media, ELISAs for SCF, EPO, TPO, GM-CSF, IL-3, IL-6, sIL-6R, IL-8, IL-11 and IGF-1 were performed. As can be seen in Figure 3 , in most of the patients with PV (7 of 11), CD3 þ cell-conditioned media contained elevated levels of IL-11. PV CD3 þ T cells produced 96.7756.8 pg/ml of IL-11 in the absence of PHA. The addition of PHA to PV CD3 þ cells did not lead to further increased levels of IL-11. Normal CD3 þ cells did not produce detectable levels of IL-11 in the presence or absence of PHA (Po0.05). The levels of GM-CSF produced by PV T cells (12.4710.1 ng/ml) was significantly increased in the presence of PHA (Po0.05), but not in the absence of PHA (P40.05) as compared with normal controls. The levels of IL-6 were only slightly higher in media conditioned by PV T cells in the presence and absence of PHA as compared with normal controls (P40.05, data not shown). There were no detectable levels of SCF, TPO, IL-3 and EPO in both PV and normal CD3 þ cell-conditioned media prepared both in the presence or absence of PHA. Similar levels of sIL-6R, IL-8 and IGF-I were observed in PV and normal CD3 þ cell-conditioned media both in the presence and absence of PHA (data not shown). þ cell-conditioned media alone ( Â 10 magnification) and the morphology ( Â 100 magnification) of megakaryocytes within these colonies (May-Grunwald-Giemsa staining). (b) A representative megakaryocyte colony promoted by SCF plus TPO ( Â 10 magnification) and the appearance ( Â 100 magnification) of megakaryocytes within these colonies (May-Grunwald-Giemsa staining). (c) A representative BFU-E colony promoted by PV CD3 þ cellconditioned media ( Â 10 magnification) and the appearance ( Â 100 magnification) of erythroblasts within these colonies (May-GrunwaldGiemsa staining).
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We then tested if IL-11 transcripts were upregulated in PV CD3 þ cells as compared with normal CD3 þ cells. IL-11 mRNA expression levels in CD3 þ cells were assessed by quantitative real-time RT-PCR and normalized to b-actin. As shown in Figure 4 , in most of the patients with PV (5 of 9), the mRNA levels of IL-11 in CD3 þ cells was elevated. Significantly higher levels of IL-11 transcripts (6.3876.21) were observed in PV CD3 þ cells as compared with that in normal CD3 þ cells (0.2870.21, Po0.05). The abnormal expression of IL-11 by PV CD3 þ cells was also confirmed by intracellular anti-IL-11 staining and flow cytometric analysis. As shown in Figure 5 , normal CD3 þ cells did not express any intracellular IL-11; by contrast, the majority of the CD3 þ cells from PV4, PV7 and PV13 expressed IL-11. IL-11 was also expressed by a small number of CD3 þ cells from PV8 ( Figure 5 ). The intracellular IL-11 expression of PV4, PV7, PV13 and PV8 by CD3 þ cells was closely correlated with the levels of IL-11 present in the media conditioned by CD3 þ cells of these PV patients.
Anti-IL-11-neutralizing antibody partially inhibits the hematopoietic colony-stimulating activity of PV T-cellconditioned media
We then determined if the colony-stimulating activity of PV T-cell-conditioned media by CB CD34 þ cells could be neutralized by the addition of anti-GM-CSF, anti-IL-6 and/or anti-IL-11 antibodies. As can be seen in Table 4 , the addition of anti-GM-CSF-neutralizing antibodies alone resulted in a modest reduction in the numbers of CFU-GM, but did not alter the numbers of BFU-E, CFU-Mk and CFU-Mk-Mix. By contrast, the addition of anti-IL-11-neutralizing antibody alone significantly reduced the numbers of BFU-E (31%), CFU-Mk (43%) and CFUMk-Mix (50%) colonies. The combination of anti-GM-CSF, anti-IL-6-and anti-IL-11-neutralizing antibodies further reduced the number of CFU-GM-derived colony formation, and the numbers of BFU-E and CFU-Mk colonies as compared with anti-GM-CSF and anti-IL-11 alone. Proplatelet formation observed in megakaryocytes contained in the CFU-Mk and CFU-Mk-Mix colonies induced by PV CD3 þ cell-conditioned media was not affected by the addition of anti-IL-11-neutralizing antibody alone or the combination of anti-GM-CSF-, anti-IL-6-and anti-IL-11-neutralizing antibodies to the culture.
These data indicate that IL-11 is responsible in part for the BFU-E-and CFU-Mk-stimulating activity present in PV CD3 þ cell-conditioned media. There are other not as yet identified soluble factors present in PV CD3 þ cell-conditioned media, which might account for the remainder of the BFU-E-and CFUMk-stimulating activity as well as the activity that promotes proplatelet formation.
Discussion
PV is thought to originate from the transformation of a multipotent progenitor cell. [1] [2] [3] [4] [5] The production of either intra- + cell-conditioned media; SCF, stem cell factor. One thousand PV PB CD34 + cells (n ¼ 7) were cultured in methylcellulose culture media in the presence of media conditioned by normal or PV CD3 + cells in the absence of exogenous cytokines. Colonies were enumerated after 12-14 days of culture. Each data point represents the mean7s.d. of seven independent experiments. *Significant differences between cultures containing normal-conditioned media and PV-conditioned media (Po0.05).
Figure 2 JAK2V617F mutational analysis of burst-forming unit erythroid (BFU-E) colonies formed by polycythemia vera (PV) CD34
þ cells isolated from three individual donors (PV2, PV3 and PV11) in the presence of media conditioned by PV CD3 þ cells alone or erythropoietin (EPO) alone using nested allele-specific PCR. A higher percentage of JAK2V617F-positive colonies were observed in BFU-E colonies assayed from PV CD34 þ cells from three separate patients in the presence of PV CD3 þ cell-conditioned media as compared with colonies formed in the presence of EPO.
Table 3
Percentage of CD3 T cells expressing CD25, CD45RO or HLA-DR in patients with PV and normal controls 
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or extracellular molecules rendering progenitors more responsive to cytokines have been proposed to account for the excessive production of erythroid and megakaryocytic cells by hematopoietic cells belonging to the malignant PV clone. 5, 39, 40 Recently, a JAK2V617F-activating mutation has been identified in more than 90% of the patients with PV. [6] [7] [8] [9] [10] The formation of EPO-independent colonies, which characterize PV, has been shown to be associated with hematopoietic progenitor cells harboring the JAK2V617F mutation. 6, 7, 41 The formation of EPOindependent colonies has also been shown to be partially dependent on cytokine-secreting accessory cells present among the BM MNC including BM stromal cells, endothelial cells, macrophages and lymphocytes. [27] [28] [29] [30] Neutralizing antibodies directed against SCF, GM-CSF, IL-3 or IL-6 to in vitro cultures of PV MNC have been shown to have no effect on the proliferation of PV progenitors, rendering it unlikely that dysregulation of these cytokines plays a role in PV pathogenesis. 42, 43 CorreBuscail et al. 42 have previously shown that anti-IL-11-neutralizing antibody significantly inhibited EEC formation by whole PV BM MNC assayed in the absence of growth factors, indicating a possible role for IL-11 in promoting in vitro PV hematopoiesis. In this study, we report that media conditioned by PV CD3 þ cells promoted BFU-E and CFU-Mk colony formation by both CB and PV PB CD34 þ cells to a greater degree than media conditioned by normal CD3 þ cells. In addition, a greater percentage of BFU-E colonies formed by PV CD34 þ cells assayed in the presence of PV CD3 þ cell-conditioned media was JAK2V617F-positive as compared to BFU-E colonies assayed in the presence of EPO. Cassel et al. 32 have demonstrated previously that PV T-cellconditioned media promoted the proliferation of erythroid colonies by normal BM MNC in the absence of EPO. These data indicate that PV CD3 þ cells elaborate growth factor(s) that preferentially stimulates megakaryocytopoiesis and erythropoiesis and, thereby, might play a role in the excessive blood cell production in PV.
EPO and IL-6/sIL-6R have been shown to promote BFU-E formation by cord blood CD34 þ cells. 44 PV, but not normal CD3 þ cell-conditioned media, promoted BFU-E formation by cord blood CD34 þ cells in the absence of exogenous cytokines. However, there were no elevated levels of EPO and sIL-6R in PV CD3 þ cell-conditioned media as compared with normal CD3 þ cell-conditioned media. These data suggest that there is an unidentified BFU-E-stimulating activity in PV, but not normal CD3 þ cell-conditioned media. It is also possible that the culture medium utilized might contain some factors that either decrease the threshold of the formation of BFU-E colonies by PV CD3 þ cell-conditioned media or synergize with factors present in PV CD3 þ cell-conditioned media to generate the activity. The overwhelming majority of the BFU-E colonies promoted by PV CD3 þ cell-conditioned media from PV CD34 þ cells were JAK2V617F-positive and only a faction of BFU-E colonies were JAK2V617F-negative. These data indicate that the BFU-Estimulating activity present in PV CD3
þ cell-conditioned media þ cell-conditioned media were significantly greater than that of normal controls both in the presence and absence of PHA (Po0.05). The levels of GM-CSF in the PV CD3 þ cell-conditioned media were significantly greater than that of normal controls in the presence of PHA (Po0.05), but not in the absence of PHA (P40.05).
likely act on both normal and PV erythroid progenitor cells, but with a much greater effect on PV cells. It remains to be clarified if the JAK2V617F-negative BFU-E represent normal BFU-E or BFU-E that belong to the malignant clone before their acquisition of JAK2V617F.
Media conditioned by PV CD3 þ cells not only promoted the megakaryocyte-containing colony formation, but also promoted megakaryocyte proplatelet formation and even platelet release by CB CD34 þ cells. Xu et al. 45 have previously reported that adult BM cells assayed in the presence of a cytokine combination including TPO, but not IL-11-produced megakaryocyte that lacked such cytoplasmic projections or proplatelet formation. It has been previously reported that TPO stimulates megakaryocyte growth and maturation but actually suppress proplatelet formation. [46] [47] [48] and EPO were shown to have no effects on human proplatelet formation. 46 In this study, we have shown that there were no detectable levels of TPO, IL-3, SCF and EPO in PV CD3 þ cellconditioned media. In addition, a combination of neutralizing antibodies including anti-IL-6, anti-GM-CSF and anti-IL-11, had little effect on the proplatelet formation. This combination of cytokine-neutralizing antibodies eliminated about one-third of the BFU-E-and CFU-Mk-stimulating activity in PV CD3 þ cellconditioned media. The factor(s) promoting the proplatelet formation and the remainder of the BFU-E-and CFU-Mkstimulating activity present in PV CD3 þ cell-conditioned media remain to be identified. Further identification of these factor(s) may provide insight into their contribution to the pathobiology of PV.
Human IL-11 is produced by BM stromal cells, fibroblasts, osteoblasts, vascular smooth muscle cells, cardiomyocytes, epithelial cells and mast cells. 29, 33, [51] [52] [53] T cells have not been reported previously to be a source of IL-11. In the present study, we showed that normal CD3 þ cells produced limited amounts of IL-11, but that in most of the patients with PV, CD3 þ cells produced much higher levels of IL-11. The elevated expression of IL-11 by CD3 þ cells in most patients with PV was also confirmed by real-time PCR and flow cytometric analysis; these data were closely correlated with the levels of IL-11 present in the corresponding CD3 þ cell-conditioned media. These results suggest that the expression and/or production of IL-11 was dysregulated in the T cells of most PV patients. High levels of IL-11 have been previously reported in the blood, BM plasma and BM stromal cell supernatants of PV patients. 29 Our data indicate that T cells might be another source of IL-11 in PV. IL-11 has been shown to stimulate both erythropoiesis and thrombopoiesis alone and synergistically with other cytokines both in vitro and in vivo.
33,54,55 IL-11 was detected at levels of 0.1-0.2 ng/ml in the media conditioned by PV CD3 þ cells. This level of IL-11 alone might be incapable of promoting BFU-E and/or CFU-Mk formation. Therefore, a yet unidentified factor produced by PV T cells likely synergizes with IL-11; this unidentified factor can also act alone on PV hematopoietic progenitor cells to promote the erythroid and megakaryocyte development of CD34 þ cells affected by JAK2V617F. It has been previously reported that BM stromal cells of PV patients produced significantly more IL-11 and IL-8 than those of normal stromal cells, 29 suggesting that dysregulation of the production of soluble growth factors by PV BM stromal cells might occur concurrently in PV. The mechanism underlining the dysregulated T cell and/or BM stromal cell-soluble growth factor production in PV remains unknown. The T cells are polyclonal and JAK2V617F-negative in the overwhelming majority of PV patients. 5, 13 The BFU-E/CFU-Mk-promoting activity present in the PV CD3 þ cell-conditioned media is not due to the altered activation of PV CD3 þ cells. An unidentified genetic abnormality might be present in PV T cells and/or BM stromal cells, which is independent of JAK2V617F but interacts with this somatic mutation to lead to the production of abnormal hematopoiesis. If this scenario is correct, two different events would be required to develop PV: the JAK2V617F mutation and the excessive production of cytokines by T cells due to an unknown defect in cytokine regulation. Alternatively, the excessive production of cytokines by T cells could occur in response to interactions between PV myeloid cells and T cells not involved by the malignant process.
Interferon-a is a therapeutically active drug for the treatment of patients with PV, 56 yet its mechanism of action remains poorly defined. Directly or indirectly interferon-a has been shown to regulate the activity of a variety of cytokines or chemokines as well as modulate the expression of CXCR4. 57 Peschel et al. have presented data that suggest that the anti-PV activity of interferon-a might be in part due to its ability to suppress the production of GM-CSF, G-CSF, IL-1 and IL-11 by BM stromal cells. 58 It remains possible that interferon-a might also downregulate IL-11 and GM-CSF production by T cells, thereby further reducing the magnitude of the PV clone. Additional therapeutically active molecules which are capable of further downregulating such T-cell-derived stimulatory cytokines might serve as therapeutic agents that might be effective alone or in combination with the new JAK2 inhibitors that are currently being evaluated in clinical trials of patients with PV.
We conclude that dysregulation of the production of soluble growth factor(s) by T cells occurs in patients with PV. The cause of this dysregulation appears to be independent of the JAK2V617F mutation. Further investigation of the cellular sources and mechanisms of dysregulation of growth factor production should provide novel insights into the pathogenesis of PV. This study thus provides evidence to support a novel concept that PV T cells might play a key role in the pathogenesis of PV. Abbreviations: anti-GM-CSF, anti-granulocyte monocyte colony-stimulating factor; anti-IL-11, anti-interleukin-11; anti-IL-6, anti-interleukin-6; BFU-E, burst-forming unit erythroid; CB, cord blood; CFU-GM, colony-forming unit granulocyte monocyte; CFU-Mk, CFU megakaryocyte; CFU-Mk-Mix, CFU megakaryocyte Mix; IgG, immunoglobulin G; PV, polycythemia vera. Five hundred CB CD34 + cells (n ¼ 3) were cultured in methylcellulose culture media containing media conditioned by PV CD3 + cells (n ¼ 4) in the absence of cytokines and in the presence of various neutralizing antibodies. Colonies were enumerated after 12-14 days of culture. Each data point represents the mean7s.d. of three independent experiments. *Significant differences between cultures containing control IgG and specific neutralizing antibody or combinations (Po0.05).
